NASDAQ:AERI Aerie Pharmaceuticals (AERI) Stock Price, News & Analysis → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Free AERI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$15.25▼$15.2550-Day Range$15.18▼$15.2552-Week Range$4.81▼$15.37Volume600 shsAverage Volume974,748 shsMarket Capitalization$753.61 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Aerie Pharmaceuticals alerts: Email Address Ad Whats On FinancePutin and other countries have a planDid you catch that bombshell Tucker Carlson interview with Vladimir Putin? It’s not about if you like Tucker or think Putin is the devil or whatever. It's all about the fact that the US dollar might be taking a back seat... and soon. Click to kickstart your journey to survive in the new economy About Aerie Pharmaceuticals Stock (NASDAQ:AERI)Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.Read More Ad Whats On FinancePutin and other countries have a planDid you catch that bombshell Tucker Carlson interview with Vladimir Putin? It’s not about if you like Tucker or think Putin is the devil or whatever. It's all about the fact that the US dollar might be taking a back seat... and soon. Click to kickstart your journey to survive in the new economy AERI Stock News HeadlinesFebruary 29, 2024 | uk.finance.yahoo.com20 Countries With Worst Vision ProblemsFebruary 21, 2024 | finance.yahoo.comParatus Sciences Appoints Theresa Heah, M.D., M.B.A. as Chief Executive OfficerApril 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.January 12, 2024 | msn.comJustin Timberlake is ready to Rock Your Body for one night only in Memphis, and for freeJanuary 10, 2024 | msn.comAlcon’s dry eye drug achieves primary endpoints in Phase III trialsJanuary 8, 2024 | finanznachrichten.deCurative Biotechnology, Inc.: Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of DirectorsJanuary 8, 2024 | markets.businessinsider.comCurative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of DirectorsDecember 15, 2023 | finance.yahoo.comGlaucoma Therapeutics Market Size Projected to Reach USD 13.5 billion by 2031, With 5.5% CAGR: Transparency Market Research, Inc.April 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.November 28, 2023 | finance.yahoo.comGlobal Over the Counter (OTC) Drugs Market Size to Grow USD 265 Billion by 2032 | CAGR of 5.0%November 25, 2023 | nypost.comAerie’s Black Friday Sale is here —Save 40% off sitewide for a limited timeNovember 23, 2023 | finance.yahoo.comNetarsudil for Fuchs Endothelial Corneal Dystrophy (FECD), 2019-2023 Emerging Drug Insights and Forecasts to 2032November 23, 2023 | finance.yahoo.comGlobal Glaucoma Treatment Market Size To Grow USD 10.5 Billion by 2032 | CAGR of 5.0%October 27, 2023 | finanznachrichten.deOpthea Limited: Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFOOctober 27, 2023 | markets.businessinsider.comOpthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFOOctober 23, 2023 | finance.yahoo.comRetinal Vein Occlusion Market to Exhibit Considerable Growth at a CAGR of ~6% During the Study Period (2019–2032) | DelveInsightSeptember 25, 2023 | uk.finance.yahoo.comRising Glaucoma Cases Forecast a Strong Optic Nerves Disorder Treatment MarketSeptember 13, 2023 | benzinga.comOptic Nerves Disorder Treatment Market Rises: North America Takes the HelmAugust 25, 2023 | time.comAerie Promo CodesAugust 24, 2023 | uk.finance.yahoo.comAngina Pectoris Drugs Global Market Report 2023August 24, 2023 | uk.finance.yahoo.comOcular Hypertension Treatment Global Market Report 2023July 18, 2023 | msn.comAlcon (ALC) Gains From Robust Contact Lense Sales, LaunchesJune 27, 2023 | finance.yahoo.comVillageMD Welcomes Richard Rubino as Chief Financial OfficerJune 22, 2023 | marketwatch.comThe Glaucoma Therapeutics market's size, share, and revenue will be thoroughly examined, with an anticipated CAGR of 13% increase from 2023 to 2030.June 22, 2023 | uk.finance.yahoo.comI-Mab Announces the Appointment of Raj Kannan as CEOJune 22, 2023 | markets.businessinsider.comI-Mab Names Raj Kannan CEO - Quick FactsJune 8, 2023 | uk.finance.yahoo.comOphthalmic Drugs Global Market Report 2023See More Headlines Receive AERI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aerie Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:AERI CUSIPN/A CIK1337553 Webwww.aeriepharma.com Phone(919) 237-5300Fax949-526-8787Employees376Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,810,000.00 Net Margins-17.09% Pretax Margin-16.47% Return on EquityN/A Return on Assets-2.00% Debt Debt-to-Equity RatioN/A Current Ratio2.27 Quick Ratio1.92 Sales & Book Value Annual Sales$194.13 million Price / Sales3.88 Cash FlowN/A Price / Cash FlowN/A Book Value($3.32) per share Price / Book-4.59Miscellaneous Outstanding Shares49,417,000Free Float47,223,000Market Cap$753.61 million OptionableOptionable Beta-0.06 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Raj Kannan (Age 58)CEO, Principal Financial Officer & Director Comp: $753.49kDr. Casey C. Kopczynski Ph.D. (Age 61)Co-Founder, Chief Innovation Officer & Head of Research and External Innovation Comp: $685.06kMr. John W. LaRocca Esq. (Age 57)Gen. Counsel & Sec. Comp: $676.62kMr. Peter F. Lang (Age 50)Chief Financial Officer Dr. Michelle Senchyna Ph.D.Head of Clinical Devel. & OperationsMr. Jeffrey M. Calabrese CPA (Age 55)VP of Fin. & Principal Accounting Officer Ms. Carolyn McAuliffeSr. Director of CommunicationsMs. Wanda FranciesHead of HRMr. Marvin J. Garrett (Age 71)Head of Regulatory Affairs & Quality Assurance Mr. Craig R. SkenesHead of Bus. Devel.More ExecutivesKey CompetitorsCullinan OncologyNASDAQ:CGEMCabaletta BioNASDAQ:CABACARGO TherapeuticsNASDAQ:CRGXREGENXBIONASDAQ:RGNXHilleVaxNASDAQ:HLVXView All Competitors AERI Stock Analysis - Frequently Asked Questions How were Aerie Pharmaceuticals' earnings last quarter? Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) posted its earnings results on Thursday, November, 4th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by $0.10. The company had revenue of $29.31 million for the quarter, compared to the consensus estimate of $29.13 million. During the same quarter in the previous year, the company earned ($0.65) EPS. What other stocks do shareholders of Aerie Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include Nicox (NICXF), Micron Technology (MU), Melinta Therapeutics (MLNT), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Puma Biotechnology (PBYI), NVIDIA (NVDA), Wells Fargo & Company (WFC) and Alibaba Group (BABA). This page (NASDAQ:AERI) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerie Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
